Cognitive dysfunction was found to be mainly associated with anti-olfactomedin 1 (OLFM1) antibodies, and sleep dysfunction (insomnia) in patients was associated with anti-Gamma-crystallin N (CRYGN) antibodies. Here, CRYGN is linked to insomnia measurement.